

[Professional Liability Application] PROSURE RESEARCH & DEVELOPMENT APPLICATION



PROSURE R&D APPLICATION

INSURANCE FOR RESEARCH & DEVELOPMENT COMPANIES

INTRODUCTION

The purpose of this application form is for us to find out who you are and to obtain information relevant to the cover provided by the PROSURE R&D policy. Completion of this application form does not oblige either party to enter into a contract of insurance.

Insurance is a contract of utmost good faith. This means that the information you provide in this application form must be complete, accurate and not misleading. It also means that you must tell us about all facts and matters which may be relevant to our consideration of your application for insurance. Any failure by you in this regard may entitle us to treat this insurance as if it never existed. If a contract of insurance is agreed between you and us this application form will form the basis of the contract.

Important: Some of the cover provided by this policy is on a claims made basis. This means that a claim must be first made against the Insured and notified to us during the period of the policy to be covered and a claim will not be covered if it arises out of any actual or alleged wrongful act occurring before the Retroactive Date.

HOW TO COMPLETE THIS FORM

Whoever fills out the form must be a principal, partner or director of the applicant firm and should make all the necessary inquiries of their fellow partners, directors and employees to enable all the questions to be answered.

If you require any extra space to complete the answers to questions contained within this application form please continue your response in the Additional Information section at the back of the form. Once you have completed the form please return directly to your insurance agent.

Please state the name and address of the principal Company for whom this insurance is required. Cover is also provided for the subsidiaries of the

PART 1 **COMPANY DETAILS**

Postal Code:
Email Address:
Website:
DD I MM I YY
: is form
t 12 months, including the number of products under development and the stag



PART 2 **PREMISES DETAILS**

2.1	Please state the address of the premises to be insured (if different from the address given earlier):				
	Premises 1				
	Address:		Postal code:		
	Details of usage (e.g. labs, storage, offices etc.):				
	Premises 2				
	Address:		Postal code:		
	Details of usage:				
	Please continue on a separate sheet if more than 2 premises to be insured	d.			
2.2	Please provide details of the premises of your supply chain partners that car cover for damage to your property and those where you have a significant re-			ose where you require	
	Name and Address	De	tails of Usage		
2.3	Are all of the premises:				
	Constructed with external walls of brick, stone or concrete and roofed with concrete, metal, asbestos or any other non-combustible material?	n slate, tiles,	Yes	No	
	b) Free from cracks or other signs of damage that may be due to subsidence and have not previously suffered damage by any of these causes?	e, landslip or heave	Yes	No	
	c) In an area free from flooding and not near the vicinity of any rivers, stream	ns or tidal waters?	Yes	No	
	d) In a good state of repair?		Yes	No	
	e) Self contained with a lockable entrance door?		Yes	No	
	f) Protected by fire and intruder alarms that are subject to an annual mainte	nance contract?	Yes	No	
	NOTE: We may refuse to pay a claim if all of the devices for the protection of tive operation whenever the premises are closed for business or left unatter.		and alarms) are n	ot put into full and effec-	
	g) Heated by a conventional electric, gas, oil or solid fuel heating system?		Yes	No	
	h) Fitted with electrical installations which are inspected at least every 5 year electrician and any defect remedied?	rs by a qualified	Yes	No	
	i) Lifts, boilers, steam and pressure vessels inspected and approved to com of the statutory requirements?	ply with all	Yes	No	

NOTE: Assuming you have answered yes to questions h) and i) above, it is important to keep records of all relevant inspections as we may ask for evidence for these before paying a claim.



2.4	If any of the premises listed in 2.1 and 2.2 con	tain composite or sandwich	n panels, please provide details:		
¬	,	Are panels exterior	Type of Panel	.	Are products LPS1181: 200
	Address	or interior?	(Make, model, core materi	al)	FMRC4880 (1994) approve
	_				
۱R۲	3 ACTIVITIES				
3.1	Do you directly work with, or store, radioactive If yes, please provide further details below incl			Yes	No No
	how you manage the process of using, storing		uantities used and		
3.2	La vicus etaels consitius to changes in anyisener	antal canditions ?			
J.Z	Is your stock sensitive to changes in environm If yes, please answer the following:	ental conditions?		Yes	No No
		neitivo?			
	a) What proportion of stock is temperature serb) Is all stock stored in fridges / freezers which		or subject		
	to maintenance agreements?	and look man by your ona,	0. 04.0,000	Yes	No
	c) Is electricity delivered by underground cable	es, with no overhead power	lines in the immediate vicinity?	Yes	No No
	d) Do all fridges / freezers have back up powe		,	Yes	No No
				100	NO
	If yes, how many hours back up is provide	ed?			
	e) Do you have an alarm system that activates	if the temperature falls ou	tside the prescribed range?	Yes	No No
	f) Is the alarm system monitored by a third pa	rty central station?		Yes	No No
	g) Is stock duplicated in more than one freeze	on the same site?		Yes	No No
	h) Is stock duplicated in more than one freeze	r at different sites?		Yes	No No
		lan far a nauvar autaga ar f	ailure in storage arrangements?	Yes	No No
	 i) Do you have a formal Business Continuity P 	ian for a power outage of ia			
3.3	 i) Do you have a formal Business Continuity P Are specialist couriers utilized for stock transp 				

3.4	Flease state stock consignment value							
		A	nnual Value	Maximum Value	of one Consignment			
	Canada:							
	Outside Canada, but within North Ame	erica:						
	Elsewhere in the world:							
	Number of floors:	Number of elevators:	Number of sepa	arate buildings:				
3.5	Will you transport stock to areas when If yes, please provide details below:	e the government currently a	dvises against travel?	Yes No				
3.6	Are you involved with R&D of your ow If no, please go to question 3.10	n products?		Yes No				
3.7	Please state your annual gross exper	nditure:						
3.8	Please state what proportion of your annual gross expenditure is attributable to:							
	Fixed internal cost (including payroll):		%					
	Variable internal cost (such as lab cor		%					
	Contractually committed payments for		%					
	Third party contracts with full 'force m	ajeure' provisions to your ben	efit:		%			
3.9	Please provide details of your contingency plans to continue R&D activities, if damage at the premises listed in 2.2 means your supply chain partners are unable to fulfil contractual commitments:							
	Supplier Name	Natu	re of Reliance	Contin	gency Plans			
3.10	Do you receive income from products If no, please go to section 4	or services provided to third	parties?	·				
	If yes, please state the income received in the box below (in CAD):							
	LOCATION OF CLIENT	LAST COMPLETE	LAST COMPLETE FINANCIAL YEAR		AL YEAR (ESTIMATE)			
		Products	Services	Products	Services			
	Canada:							
	USA:							
	Elsewhere in the world:							
	Total:							

	Client Name	Client Business	Nature of Work Undertaken for this Contract	Your Annual Income from this Contract	Start [ate	Co	mpletion Date
					MM I	YY	N	1M I YY
					MM I	YY	N	MI YY
					MM I	YY	N	IM I YY
					MM I	YY	N	MI YY
					MM I	YY	N	MI YY
					MM I	YY	N	MI YY
3.12	What approximate percent	age of your income, in your	current financial year, will be paid to	sub-contractors?				
3.13	Will sub-contractors carry	the following insurance:		-				%
	a) Products liability for CM	Os?			Yes		No	
	b) Errors and omissions fo	r CROs, contract research se	ervice providers and other consulta	nts?	Yes		No	
	c) Medical Malpractice (or	equivalent government liabili	ity) for clinical investigators conduct	ting your clinical trials?	Yes		No	
3.14	Will your products be mark If no, please go to section	xeted for human consumption n 4	n in the next 12 months?		Yes		No	
	If yes, please attach litera	ature for each of these produ	ucts, including brochures, technical	literature, sale conditions				
	Please state the percentag	ge of your income generated	by sales of these products, includir	ng component parts:				%
3.16	Are these products:							
	a) Vaccines?				Yes		No	
	b) Gene therapy?				Yes		No	
	c) Cell therapy?				Yes		No	
	dexfenfluramine, diazep fibrates, germanium, ha methylphenidate, nefaz phenylpropanolamine (l serzone, silicone gel us	pines, dicyclomine, diethylstil alogenated 8, hydroxy quinoli odone, oxazepines, paxil, pe PPA), piper methysticum, pri sed as part of an injection or a	n, cisapride, danthron, debendox, I bestrol (DES), dioxins, ephedrine, t ines, hydroquinone, isotretinoin, lot ertussis vaccine, phenfluramine, phe modos, prozac, remoxipride, retinoi as part of an implantable device, st sol or thimersal, tretinoin, troglitazo	enfluramine, ronex, I-tryptophan, entermine, ds, risperidone, atins,	Yes		No	
	e) Implantable medical dev	vices?			Yes		No	
	f) Skin whitening products	?			Yes		No	
	g) Birth control products or If yes to any of the abo	devices?			Yes		No	

- May	Cansure
$\overline{}$	Canoune

3.17	Could the failure of these products or services result in:		
	a) Loss of life or injury to a person?	Yes	No
	b)Damage or destruction to physical property?	Yes	No
	c) Significant third party financial loss?	Yes	No
	If yes to any of the above, please provide details:		
3.18	Is the delivery of these products and services time critical to the third parties using them (such as a clinical trial)? If yes, please provide details:	Yes	No
PART	4 CONTRACT MANAGEMENT		
4.1	Is all work carried out (by you, or for you) under a written contract?	Yes	No
4.2	Are all contracts reviewed by independent, qualified legal advisers?		
	If no, please outline the procedures used for developing and reviewing contracts:		
4.3	Are rights of recourse retained against CMOs, CROs, clinical investigators and all other supply chain partners? If no, please explain why:	Yes	No
4.4	In your written contracts do you ever accept liability for consequential loss or financial damages	Yes	No
	greater than the value of the contract? If yes, please provide details:		
4.5	Do your written contracts ever contain 'Hold Harmless' or 'Indemnification' clauses in which you accept liability for loss of life, injury, property damage, or financial losses in circumstances other than	Yes	No
	where they are caused by your negligence? If yes, please provide details:		
	ii yes, piease provide detaiis.		
4.6	In your written contracts, do you ever provide guarantees of products or services?		Ne
7.0	If yes, please provide details:	Yes	No



PART 5

CLINICAL TRIALS

(Only complete this section if you require cover for Clinical Trials)

5.1	In respect of each of the clinical trials listed below,	please attach the following	ng (in Engi	lish):			
a) Trial Protocol							
	b) Patient Information						
	c) Patient Informed Consent form						
	d) A list of the Clinical Investigator sites						
5.2	Please provide below details of completed trials for	which cover is required:					
	Protocol Number and Description	Date Treatment Com	pleted	Number o	of Subjects		Country
		DD I MM I YY	/				
		DD I MM I YY	/				
		DD I MM I YY	/				
		DD I MM I YY	,				
5.3	Please provide below the details of ongoing trials,	or trials that are expected	to comme	ence in the next	12 months, for wi	nich prima	ry cover is required:
	Protocol Number and Description	Start Date	Expec	ted End Date	Number of Su	bjects	Country
		DD I MM I YY	DD	I MM I YY			
		DD I MM I YY	DD	I MM I YY			
		DD I MM I YY	DD	I MM I YY			
		DD I MM I YY	DD	I MM I YY			
5.4	Are you the sponsor in respect of each of the clinic If no, please state the nature of your interest:	al trials listed above?				Yes	No
5.5	Are any of the clinical trials listed above testing pro If yes, please provide details:	ducts that are 'First in Ma	an'?			Yes	No
5.6	In respect of the clinical trials listed above, will any	of the following be tested	d:				
	a) Vaccines?					Yes	No
	b) Gene therapy?					Yes	No
	c) Cell therapy?					Yes	No
	d) Acutane, amenorone forte, bupropion, canthaxanthin, cisapride, danthron, debendox, DEHP, dexfenfluramine, diazepines, dicyclomine, diethylstilbestrol (DES), dioxins, ephedrine, fenfluramine, fibrates, germanium, halogenated 8, hydroxy quinolines, hydroquinone, isotretinoin, lotronex, l-tryptophan, methylphenidate, nefazodone, oxazepines, paxil, pertussis vaccine, phenfluramine, phentermine, phenylpropanolamine (PPA), piper methysticum, primodos, prozac, remoxipride, retinoids, risperidone, serzone, silicone gel used as part of an injection or as part of an implantable device, statins, swine-flu vaccine, thalidomide, thiazepines, thimerosol or thimersal, tretinoin, troglitazone, tryptophan?						

	e) Implantable medical devices?	Yes	No
	f) Skin whitening products?	Yes	No
	g) Birth control products or devices? If yes to any of the above, please provide details:	Yes	No
5.7	In respect of any of the clinical trials listed in questions 5.1 to 5.3, are / were more than 25% of the research subjects under 16 years? If yes, please provide details:	Yes	No
5.8	In respect of any of the clinical trials listed in questions 5.1 to 5.3, are / were more than 25% of the research subjects women of child bearing age? If yes, please provide details:	Yes	No
5.9	Are all clinical trials conducted in accordance with all relevant local laws and regulations? If no, please explain why:	Yes	No
5.10	In respect of all completed and ongoing trials, have you:		
	a) Made all necessary filings?	Yes	No
	b) Received all required authorisations?	Yes	No
	c) Had the protocol approved by an independent Ethics Committee?	Yes	No
	If no to any of the above, please explain why:] -
5.11	Do you ever act as both trial sponsor and clinical investigator? If yes, please provide details:	Yes	No
5.12	Have you stopped or suspended any clinical trials for safety reasons? If yes, please provide details:	Yes	No

	as a result of participation in a clinical trial sponsored by you, in the past 5 years? If yes, please provide details:	
RT	6 COVER LIMITS AND SUMS INSURED	
.1	Would you like cover for damage to your property?	Yes No
	If no, please go to question 6.7	
	If yes, please attach information regarding the value of the following property, including estimated maximum applicable, at the premises listed in question 2.1 and 2.2:	values at risk at any one time where
	a) Buildings	
	b) Tenants improvements, fixtures & fittings	
	c) Laboratory equipment	
	d) Fixed electronic equipment	
	e) Portable electronic equipment	
	f) Lab consumables and R&D Stock (including the cost of materials and other re-creation costs)	
	g) Third party stock in your custody and control h) Research animals (showing the total value and the estimated maximum value of a single animal)	
	i) Any other property not listed above	
.2	Would you like the policy to cover any of the following:	
	a) Spoilage of perishable stock?	Yes No
	b) Pollution or contamination?	Yes No
	c) Machinery breakdown?	Yes No
	d) Property in transit?	Yes No
	e)Terrorism?	Yes No
	f) Ideologically motivated attack (that is not declared an act of terrorism by the government)?	Yes No
	g) Earthquake?	Yes No
	h) Flood?	Yes No
3	Would you like business interruption cover?	
	If yes, please state the 'First Loss' sum insured required:	
4	Please state the sublimits required for business interruption following damage at the premises of your suppli-	v chain narthers listed in question 2.2
4		
	Supply Chain Partner Name Business	s Interruption Sublimit



Please state the Indemnity Period required (6 - 24 months):

Months

6.6	Would you like cover for Commercial Gene	ral Liability?		Yes No	
0.0	If yes, please state the Limit of Liability re	100			
6.7	Would you like cover for Products and Serv	Yes No			
0.7	If yes, please state the Limit of Liability re	100 100			
	ii yes, piease state the clinit of clability it	yquirea.			
PAR1	7 CLAIMS EXPERIENCE AND I	NSURANCE HISTORY			
7.1	Please provide below details of completed	trials for which cover is required:			
	Туре	Expiry Date	Retroactive Date	Insurer	
	Property and Business Interruption:	DD I MM I YY	Not applicable		
	Commercial General Liability:	DD I MM I YY	Not applicable		
	Products Liability:	DD I MM I YY	DD I MM I YY		
	Errors and Omissions:	DD MM YY	DD I MM I YY		
	Clinical Trials:	DD I MM I YY	DD I MM I YY		
7.2	Regarding all of the types of insurance to w	hich this application form relates.	, AFTER ENQUIRY:		
	a) are you aware of any loss or damage, who (or to any existing or previous business of last 5 (five) years, or		, ,		
	b) are you aware of any circumstances whi	ch may give rise to a claim agains	st any of the Companies to be insur	red or	
	any partners or directors thereof, or	and the second s	· O · · · · · · · · · · · · · · · · · ·		
	 c) have any claims or cease and desist ord directors thereof, or 	ers been made against any of the	e Companies to be insured, or partn	ers or	
	d) have any partners or directors of the Cor or fraudulent activity or been investigated		d guilty of any criminal, dishonest		
	With reference to questions a, b, c and d at	oove: Yes No			
	If the answer to the above is yes, then plea amount involved / claimed, the status of the Insurers, and the dates of all developments	e claim(s) or circumstance(s) and			
PART	8 DECLARATION				
	• I /we declare that after proper enquiry the or suppressed any material fact.	statements and particulars given	above are true and that I /we have	not mis-stated	
	I/we agree that this Application Form, together any contract of insurance effected thereory.		mation supplied by me/us shall forn	n the basis of	
	• I/we undertake to inform Underwriters of a	any material alteration to these fac	cts occurring before the completion	of the contract.	
	Signed:		Full Name:		

Position held at Insured:

Date: DD | MM | YY



